- Trends in Orphan Diseases partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Orphan Diseases partnering agreement structure
- Orphan Diseases partnering contract documents
- Top Orphan Diseases deals by value
- Most active Orphan Diseases dealmakers
The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.
The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Orphan Diseases dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Orphan Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Orphan Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Orphan Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Orphan Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2010. The chapter is organized by specific Orphan Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Orphan Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Orphan Diseases partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Orphan Diseases technologies and products.
Global Orphan Diseases Partnering 2010 to 2020 is intended to provide the reader with an in-depth understanding and access to Orphan Diseases trends and structure of deals entered into by leading companies worldwide.
Global Orphan Diseases Partnering 2010 to 2020 includes:
- Trends in Orphan Diseases dealmaking in the biopharma industry since 2010
- Analysis of Orphan Diseases deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Orphan Diseases deal contract documents
- Comprehensive access to over 230 Orphan Diseases deal records
- The leading Orphan Diseases deals by value since 2010
- Most active Orphan Diseases dealmakers since 2010
In Global Orphan Diseases Partnering 2010 to 2020, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
The Global Orphan Diseases Partnering 2010-2020 report provides comprehensive access to available deals and contract documents for over 230 orphan diseases deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Chapter 1 - Introduction
Chapter 2 - Trends in Orphan Diseases dealmaking
2.2. Orphan Diseases partnering over the years
2.3. Orphan Diseases partnering by deal type
2.4. Orphan Diseases partnering by industry sector
2.5. Orphan Diseases partnering by stage of development
2.6. Orphan Diseases partnering by technology type
2.7. Orphan Diseases partnering by therapeutic indication
Chapter 3 -Financial deal terms for Orphan Diseases partnering
3.2. Disclosed financials terms for Orphan Diseases partnering
3.3. Orphan Diseases partnering headline values
3.4. Orphan Diseases deal upfront payments
3.5. Orphan Diseases deal milestone payments
3.6. Orphan Diseases royalty rates
Chapter 4 - Leading Orphan Diseases deals and dealmakers
4.2. Most active in Orphan Diseases partnering
4.3. List of most active dealmakers in Orphan Diseases
4.4. Top Orphan Diseases deals by value
Chapter 5 - Orphan Diseases contract document directory
5.2. Orphan Diseases partnering deals where contract document available
Chapter 6 - Orphan Diseases dealmaking by therapeutic target
6.2. Deals by Orphan Diseases therapeutic target
Appendix 1 - Directory of Orphan Diseases deals by company A-Z since 2010
Appendix 2 - Directory of Orphan Diseases deals by deal type since 2010
Appendix 3 - Directory of Orphan Diseases deals by stage of development since 2010
Appendix 4 - Directory of Orphan Diseases deals by technology type since 2010
Further reading on dealmaking
Deal type definitions
Table of figures
Figure 1: Orphan Diseases partnering since 2010
Figure 2: Orphan Diseases partnering by deal type since 2010
Figure 3: Orphan Diseases partnering by industry sector since 2010
Figure 4: Orphan Diseases partnering by stage of development since 2010
Figure 5: Orphan Diseases partnering by technology type since 2010
Figure 6: Orphan Diseases partnering by indication since 2010
Figure 7: Orphan Diseases deals with a headline value
Figure 8: Orphan Diseases deals with upfront payment values
Figure 9: Orphan Diseases deals with milestone payment
Figure 10: Orphan Diseases deals with royalty rates
Figure 11: Active Orphan Diseases dealmaking activity since 2010
Figure 12: Top Orphan Diseases deals by value since 2010
- Abiogen Pharma
- ACMG Foundation for Genetic and Genomic Medicine
- Adamas Pharmaceuticals
- Advanced Accelerator Applications
- Aegerion Pharmaceutical
- Aevi Genomic Medicine
- Akcea Therapeutics
- Alcyone Lifesciences
- Alexion Pharmaceuticals
- Amarantus BioSciences
- American National Multiple Sclerosis Society
- Amicus Therapeutics
- AOP Orphan Pharmaceuticals
- Aperion Biologics
- Aprecia Pharmaceuticals
- Arcturus Therapeutics
- Aridis Pharmaceuticals
- Array Biopharma
- Aslan Pharma
- Astellas Pharma
- Audentes Therapeutics
- Auven Therapeutics
- Beijing Double-Crane Pharmaceutical
- Bellus Health
- BioPontis Alliance
- BioTie Therapies
- Buck Institute for Age Research
- California Institute for Biomedical Research
- Canadian Organization for Rare Disorders
- Cancer Prevention Pharmaceuticals
- Castle Creek Pharmaceuticals
- Catabasis Pharmaceuticals
- Catalent Pharma Solutions
- Censa Pharmaceuticals
- Children's Hospital Boston
- Children's Hospital of Philadelphia
- Chugai Pharma Marketing
- Clalit Health Fund
- Cloud Pharmaceuticals
- Confo Therapeutics
- Corino Therapeutics
- CSL Behring
- Cutaneous Lymphoma Foundation
- Cycle Pharmaceuticals
- Cystic Fibrosis Foundation
- DBV Technologies
- Edico Genome
- Edimer Pharmaceuticals
- Eiger BioPharmaceuticals
- Enable Injections
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Collaborative R&D
- Contract service
- Equity purchase
- Joint venture
- Royalty financing
- Spin out
- Sub license
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.